Cencora (COR) Resumen de Acciones
Cencora, Inc. obtiene y distribuye productos farmacéuticos en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 4/6 |
| Dividendos | 4/6 |
Recompensas
Análisis de riesgos
COR Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Cencora, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$321.57 |
| Máximo en las últimas 52 semanas | US$377.54 |
| Mínimo de 52 semanas | US$244.82 |
| Beta | 0.57 |
| Cambio en 1 mes | 2.47% |
| Variación en 3 meses | 14.25% |
| Cambio de 1 año | 10.35% |
| Variación en 3 años | 79.62% |
| Variación en 5 años | 163.65% |
| Variación desde la OPV | 10,789.14% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 03
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.
Actualización de narrativa • Aug 19
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Recent updates
Actualización de narrativa • Sep 03
COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes
Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.Actualización de narrativa • Aug 19
COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside
Analysts have adjusted their price target for Cencora to $372.58 from $350.58, citing updated assumptions for discount rates, profit margins, and future P/E multiples in their valuation work. What's in the News for Cencora Cencora reported a strong fiscal third quarter with revenue growth and higher adjusted diluted EPS, and raised its 2026 adjusted EPS guidance range.Actualización de narrativa • Aug 05
COR: Fair View Will Weigh Nucleus Rollout, Cell Therapy And Legal Risk
Analysts now cite slightly firmer revenue growth, profit margin assumptions and a higher future P/E, which together support a refreshed Cencora fair value estimate increasing from $310 to $320. What’s in the News for Cencora Cencora launched a multi site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, combining updated hardware and software to support medication workflow efficiency, visibility and control.Seeking Alpha • Jul 22
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Summary Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth. Execution risks include integration of acquisitions, increased leverage, regulatory scrutiny, and high customer concentration, but specialty platform buildout is expected to deepen margins and retention. Read the full article on Seeking AlphaActualización de narrativa • Jul 22
COR: Fair Value View Will Weigh Nucleus Rollout And Cell Therapy Partnership
Analysts have raised their Cencora price target from $288.21 to $310.00, reflecting updated views on fair value, revenue, profit margins, and future P/E assumptions. What’s in the News for Cencora Cencora announced a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices, with deployment planned in phases across more than 20 practice sites.Actualización de narrativa • Jul 08
COR: Insider Buying And Fair Value View Will Shape Upcoming Share Performance
Analysts have nudged their price target for Cencora higher from $280.00 to about $288.21, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for Cencora Cencora stock moved 3.6% higher on June 23, 2026, alongside commentary that the shares are viewed as modestly undervalued relative to one intrinsic value estimate and supported by what sources describe as solid business fundamentals.Artículo de análisis • Jun 16
Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative
Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record. See our latest analysis for Cencora. Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a...Actualización de narrativa • Jun 15
COR: Buybacks And New CFO Appointment Will Support Long Term Upside
Analysts have modestly reduced their price target on Cencora to $350.58 from $356.83. This reflects slightly updated views on fair value and future P/E assumptions.Actualización de narrativa • Jun 01
COR: Buybacks And New CFO Will Support Long Term Upside
Analysts now estimate Cencora's fair value at $356.83 per share, down from $373.08. This change reflects updated assumptions around slightly slower revenue growth, a modestly lower profit margin outlook, and a small shift in future P/E expectations.Nueva narrativa • May 09
Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory
Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • May 08
COR: Share Repurchases And CFO Transition Will Support Long Term Upside
Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.Actualización de narrativa • Apr 24
COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside
Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.Actualización de narrativa • Apr 08
COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside
Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.Actualización de narrativa • Mar 25
COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access
Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.Actualización de narrativa • Mar 10
COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside
Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.Actualización de narrativa • Feb 24
COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside
Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).Artículo de análisis • Feb 12
Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...Actualización de narrativa • Feb 08
COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential
Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).Actualización de narrativa • Jan 23
COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.Actualización de narrativa • Jan 09
COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside
Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.Actualización de narrativa • Dec 16
COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks
Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).Actualización de narrativa • Dec 02
COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks
Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.Actualización de narrativa • Nov 18
COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks
Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.Actualización de narrativa • Nov 04
COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution
Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.Actualización de narrativa • Sep 04
Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.Rentabilidad de los accionistas
| COR | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -2.8% | -1.8% | -0.9% |
| 1Y | 10.4% | 17.3% | 13.9% |
Rentabilidad vs. Industria: Los resultados de COR fueron inferiores a los de la industria US Healthcare, que obtuvo un rendimiento del 17.3% el año pasado.
Rentabilidad vs. Mercado: COR obtuvo unos resultados inferiores a los del mercado US, que fueron del 13.9% el año pasado.
Volatilidad de los precios
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: COR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de COR (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1871 | 49,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. obtiene y distribuye productos farmacéuticos en Estados Unidos y a escala internacional. El segmento U.S. Healthcare Solutions distribuye productos farmacéuticos genéricos e inyectables, productos sanitarios de venta libre, suministros y equipos de atención sanitaria a domicilio y servicios relacionados a hospitales de agudos y sistemas de salud, farmacias minoristas independientes y de cadena, farmacias de venta por correo, clínicas médicas, farmacias de atención a largo plazo y de centros alternativos, y otros clientes; distribuye plasma y otros productos sanguíneos, vacunas y otros productos farmacéuticos especializados; presta servicios de gestión de farmacias, dotación de personal y otros servicios de consultoría; software de gestión de suministros a proveedores de atención sanitaria minoristas e institucionales; soluciones de envasado a proveedores sanitarios institucionales y minoristas; servicios de apoyo a ensayos clínicos, postaprobación de productos y apoyo a la comercialización; análisis de datos, investigación de resultados y otros servicios para fabricantes de biotecnología y productos farmacéuticos; productos farmacéuticos, vacunas, parasiticidas, diagnósticos, ingredientes de micropiensos y otros productos para los mercados de animales de compañía y animales de producción; servicios de fuerza de ventas a fabricantes; y ofrece otros servicios a médicos especializados en diversas enfermedades, como oncología, así como a otros proveedores sanitarios, como hospitales y clínicas de diálisis.
Resumen de fundamentos de Cencora, Inc.
| Estadísticas fundamentales de COR | |
|---|---|
| Capitalización bursátil | US$61.36b |
| Beneficios(TTM) | US$2.62b |
| Ingresos (TTM) | US$332.77b |
23.4x
Ratio precio-beneficio (PE)0.2x
Ratio precio-ventas (PS)¿Está COR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de COR | |
|---|---|
| Ingresos | US$332.77b |
| Coste de los ingresos | US$319.59b |
| Beneficio bruto | US$13.18b |
| Otros gastos | US$10.56b |
| Beneficios | US$2.62b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 13.75 |
| Margen bruto | 3.96% |
| Margen de beneficio neto | 0.79% |
| Ratio deuda/patrimonio | 361.9% |
¿Cómo se ha desempeñado COR a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.7%
Rentabilidad actual por dividendo17%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 19:22 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cencora, Inc. está cubierta por 31 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |